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In this investigation, time-released monolithic osmotic pump (TMOP) tablets containing
diltiazem hydrochloride (DIL) were prepared on the basis of osmotic pumping mechanism.
Thedevelopeddosage formswere coatedbyKollidon®SR-PolyethyleneGlycol (PEG)mixtures
via compression-coated technology instead of spray-coating method to form the outer
membrane. For more efficient formulation screening, a three-factor five-level central com-
posite design (CCD) was introduced to explore the optimal TMOP formulation during the
experiments. The in vitro tests showed that the optimized formulation of DIL-loaded TMOP
had a lag time of 4 h and a following 20-h drug release at an approximate zero-order rate.
Moreover, the releasemechanismwasprovenbasedonosmoticpressureand itsprofile could
be well simulated by a dynamic equation. After oral administration by beagle dogs, the
comparison of parameters with the TMOP tablets and reference preparations show no sig-
nificant differences for Cmax (111.56 ± 20.42, 128.38 ± 29.46 ng/ml) and AUC0-48 h
(1654.97 ± 283.77, 1625.10 ± 313.58 ng h/ml) but show significant differences for Tmax
(13.00 ± 1.16, 4.00 ± 0.82 h). These pharmacokinetic parameters were consistent with the
dissolution tests that the TMOP tablets had turned out to prolong the lag time of DIL release.
© 2014 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
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the drug within a proper period of time after a predetermined
lag time are developing quickly as more and more extensive
application of chronotherapeutics in clinical practice. Several
diseases, including arthritis, asthma, allergies, peptic ulcer
disease, dyslipidemia and cancer exhibited predictable circa-
dian rhythms [1,2]. In particular, aggravation of cardiovascu-
lar diseases like angina, hypertension and myocardial
infraction, were more frequent to break out in the early
morning before patients wake up [3]. It was badly inconve-
nient to take the conventional drug dosage providing relief of
symptoms and protection from those adverse events when
necessary. Consequently, we need the administration of a
drug formulated in time-released delivery system, i.e. taken at
bedtime with a programmed start of drug release based on
circadian rhythms.
There were various approaches for the time-released drug
delivery system, such as system based on osmosis, or capsule,
system with change in membrane permeability and system
with erodible, soluble or rupturable membrane. Now all of
themwere gaining popularity for prime advantage that drug is
released solely when necessity comes. As a result, risks of
development of drug resistance, usually seen in conventional
and sustained-release formulations, could be reduced. Among
the time-released products mentioned above, osmotic pump
preparations have stood out, with superiority for not only
matching with circadian rhythms, but also exhibiting reliable
comparable in vitro/in vivo drug release [4,5]. The release rate
from these types of system depended on the coating compo-
nents and the osmotic gap across the membrane, without
influences from the pH, peristalsis or other interference in
gastrointestinal (GI) tract.
Osmotic pump tablets (OPTs) belonged to the class of rate-
controlled systems which provided continuous delivery and
different types such as monolithic, two-compartment, two-
layer pushepull and three-layer osmotic tablets systemswere
developed [6]. Theeuwes introduced the monolithic osmotic
pump (MOP) and brought forward its basic theory in the 1970s
[7,8]. It consisted of an osmotic core coated by a semi-
permeable membrane drilled with a delivery orifice. The
MOP was very simple to prepare and could release water-
soluble drugs at the rate of approximate zero-order [9]. Due
to its simple production procedures, the MOP avoiding a so-
phisticated technique had been an emphasis of recent re-
searches. However, the common osmotic pumps were still
facing two technical problems, use of organic solvent for
coating outer membrane and drilling process for delivering
pharmaceutical ingredients, which extremely limit the
industrialization of osmotic pumps in pharmaceutical in-
dustry. Although many attempts had been made to resolve
these two problems, the current situation of industrialization
was still difficult.
With the joint efforts of all explorers, a new face had been
put on these matters via microporous membrane and non-
solvent coating technology. Recently, osmotic pump tablets
had been developed in which the delivery orifice was formed
by the addition of water-soluble components in the coatingmaterial. Once the tablets came in contact with the GI fluid,
thewater-soluble component dissolved to forming an osmotic
pumping system. Subsequently, water diffused through the
microporous membrane to dissolve core components, form-
ing an osmotic gap to control the drug releasing [10,11]. As a
consequence, the manufacturing process was simplified with
the elimination of drilling orifice. Moreover, compression-
coated technology, referred as non-solvent coating method,
was employed to the TMOP tablets. Comparedwith traditional
coating method, this new coating technique could avoid dis-
advantages in the pharmaceutical industrialization, such as
environmental pollution accompanying with use of organic
solution. In general, the compression-coated tablet was
composed of an inner core tablet and an outer coating shell.
And its thicker outer shell show inherent advantages for
chronotherapeutics because of time taken for penetrating of
the membrane i.e. is known as lag time [12]. It was generally
accepted that the property of compression-coated tablets was
under the influence of the inner core tablet and outer coating
shell in the formulation. We had taken the central composite
design (CCD) method to determine the interaction of inner
core tablet and an outer coating shell for TMOP tablets with
optimal formulations. The CCD method which could provide
information on direct effects, pair-wise interaction effects,
curvilinear variables effects, was suitable for formulation and
process optimization in the field of pharmaceutics involving
with multiple factors and levels since it was an efficient
method to reduce the number of experiments [13e16].
The objective of our investigation is to develop time-
released monolithic osmotic pump (TMOP) tablets with
microporosity by compression-coated technology, in which
involve with neither organic solvent nor drilling process. Dil-
tiazem Hydrochloride (DIL), a calcium channel blocker which
inhibits influx of calcium (Ca2þ) ions [16], was chosen as the
model drug. The DIL is frequently administered orally for the
treatment of angina and hypertension as sustained-release
formulations to improve compliance, but the constant de-
livery of DIL into the body also leads to drug resistance or side
effects. Moreover, the high water-solubility (>50%, w/v at
25 C) of DIL are suitable to apply in TMOP preparations. For
the compression-coatedmicroporous TMOP tablet, it provided
new ideas to both pharmaceutical manufacture and clinical
chronotherapeutics.2. Materials and methods
2.1. Materials
Polyvinylacetateepolyvinylpyrrolidon (Kollidon®SR) is kindly
donated by Basf Auxiliary Chemicals Co., Ltd Shanghai,
China. Microcrystalline cellulose (MCC, Ph102) was supplied
by AsahiKasei. Polyethylene glycol (PEG) was received from
Anhui Sunhere Pharmaceutical excipients Co., Ltd. The
model drug of DIL, obtained from Shanghai Jinhuan Chemical
Co., Ltd, was passed through 100 mesh sieve prior to the
experiment. The reference preparation (sustained-release
capsule, Herbesser) was purchased from Tianjin Tanabe
Seiyaku Co., Ltd.
Table 1e The composition of coating and thickness of the
compression-coated TMOP tablets.
Formulation Composition
of core
tablets (mg)
Composition of
coating layer (mg)
Thickness
(mm)
DIL MCC Kollidon®SR PEG
4000
A 1 120 60 200 40 4.85 ± 0.01
2 120 60 180 60 4.85 ± 0.02
3 120 60 160 80 4.84 ± 0.01
B 1 120 60 200 40 4.77 ± 0.02
2 120 60 200 40 4.85 ± 0.01
3 120 60 200 40 4.98 ± 0.01
C 1 120 40 180 60 4.96 ± 0.01
2 120 60 180 60 4.97 ± 0.01
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 0 8e2 1 72102.2. Preparation of TMOP tablets
DIL-loaded MOP was prepared by compression-coated
methods and the sizes of inner cores and coating tablets, the
coating quantity (240 mg) have been determined by pre-
experiment. The process went like this: Firstly, a mixture of
120 mg DIL and some MCC were directly compacted into a
circular tablet (8mm in diameter) as inner core. Half of coating
material consisting of Kollidon®SR and PEG was poured into a
die having a diameter of 11 mm and pressed to smooth, then
the 8 mm inner core tablet was artificially placed in the center
of the pressed coatingmaterial. Finally, the remaining coating
material was filled into the die and compacted to get the final
compression-coated products. Fig. 1 shows the sketch map of
the TMOP tablets.
3 120 80 180 60 4.98 ± 0.022.3. Study of significant variables
The compression-coated TMOP consists of a pharmaceutical
core and an outer coating shell made of release modifiers. So,
TMOP tablets may be modified to provide different release
pattern by varying composition of polymer material used in
the core and outer shell. In this section, we investigated
several separate elements to opt for the most important ones
influencing the physical properties of the produced DIL-
loaded TMOP tablets. As given in Table 1, variables including
the coating thickness, the amount of PEG in outer shell, and
MCC distribution in core tablet were taken into experiments.
The dissolution experiments of compression-coated tab-
lets were carried out using the paddle method with three
preparations per study in a medium of 900 ml 37 C purified
water and a stir of 100 rpm. Samples of 5 ml medium were
drawn out with equivalent media replacement on schedule.
The concentration of DIL dissolved in the medium was
determined spectrophotometrically at the wavelength of
240 nm. According to FDA regulation, the similarity factor (f2)
as a measurement for assessing the similarity of two disso-
lution profiles was introduced to describe that whether a
variable was significant enough to predominate the experi-
mental results or not. As f2 < 50%, the variable could beFig. 1 e The introduction of the TMOP tablets (A. inner core;
B. half of coating material; C. inner core with half coating
material; D. the final product of TMOP tablets).considered a significant element influencing the release pro-
file. The f2 was obtained by Eq. (1) below:
f2 ¼ 50 log
nh
1þ ð1=nÞ
Xn
t¼1ðRt  TtÞ
2
i0:5
 100
o
(1)
2.4. Central composite design (CCD) study
The process of formulation screening was proceeding ac-
cording to CCD method. After opting for the most important
elements influencing the in vitro properties of the produced
compression-coated TMOP, a multiple-factor, five-level CCD
was employed to find out the optimum levels of these vari-
ables. The CCD consisted of 2k þ 2k þ n runs, where k is the
number of factors, 2k is the number of the factorial points at
the corners of the cube, 2k is the number of the axial points on
the axis of each design factor at a distance of ±a (a ¼ 2k/
4 ¼ 1.682 for k ¼ 3) from the center of the cube, and n is the
number of the replication of center points at the center of the
cube [17]. On basis of the two-level (±1) factorial design, two
star points (±a), and center point (0) were also introduced in
this methodology. Therefore, independent variables (X1, X2 …
Xn) were studied at five different levels coded as a, 1, 0, þ1,
and þa. In vitro properties of the produced TMOP, i.e. cumu-
lative drug ratio of 4 h (Y1), cumulative drug ratio of 14 h (Y2)
and cumulative drug ratio of 24 h (Y3) were selected as
dependent variables. All the experimental formulations of the
CCDmatrixwere constructed by Design-Expert software (Trial
Version 8.0.5.0, Stat-Ease Inc., MN).
During the course of predicting of the optimal formulation,
fitness of the model among the linear, two-factor (2F) inter-
action and quadratic model was assessed on basis of the
analysis of variance p-value and focus on the model maxi-
mizing multiple correlation coefficient r2 (predicted) as
assessment criteria in the model summary statistic list.
Optimization was performed by using a desirability function
to obtain the optimal points involving the predetermined
constraints where the cumulative drug ratio of 4 h (Y1) was
located in a reasonable range of less than 5%, cumulative drug
ratio of 14 h (Y2) in its minimum level and cumulative drug
ratio of 24 h (Y3) in its maximum levels [14,18,19].
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Fig. 2 e The releasing curve of TMOP with different formulations (A. different amount of PEG in outer coat; B. different
coating thickness; C. different amount of MCC in core).
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The study was approved by the Ethics Review Committee for
Animal Experimentation of Shenyang Pharmaceutical Uni-
versity (Shenyang, China). Six beagle dogs weighing 10 ± 2 kg
were obtained from Experimental Animal Center of Shenyang
Pharmaceutical University (Shenyang, China). All the beagle
dogs were divided randomly into two groups and fasted
overnight but allowed to free access to water before experi-
ment. Reference preparations (sustained-released capsules)
and tested TMOP tablets were orally administrated to two
groups at a dose of 120 mg/body. Blood samples (2 ml) of each
animal were sampled via foreleg remaining needle at 0,1, 2, 3,
4, 5, 6, 7, 8, 9, 10, 12, 14, 16, 24, 36 and 48 h after administration.
All the blood samples were immediately centrifuged at
4000 rpm for 10 min to separate the plasma. Thereafter, a
1000 ml of plasma was mixed with 500 ml of K2HPO3 (0.5 mol/l)
and 100 ml internal standard (Verapamil HCl, 2 mg/ml) and
shaken for 3 min using a vortex mixer. Then 5000 ml of mixed
diethyl ether and n-hexane (1:1, v/v) was added and the
mixture was vortexed at room temperature for 5 min. After
centrifugation at 4000 rpm for 10 min, the organic layer was
transferred into another clean tube and receiving 100 ml of HCl(0.01 mol/l). The mixture was vortexed at for 5 min and
centrifuged at 4000 rpm for 5min. The upper organic layerwas
abandoned and 60 ml of lower liquor was injected into the
HPLC system (Pgeneral P6eN6, Beijing Purkinje General In-
strument Co., Ltd) for analysis.
The main pharmacokinetic (PK) parameters were acquired
with the help of a PK program DAS 2.0. The various PK pa-
rameters that were analyzed included maximum peak con-
centration of the drug in plasma (Cmax), the time to reach
maximum concentration (Tmax), and the area under the
plasma concentrationetime curve (AUC0e48 h). All results were
presented as mean ± SD values.3. Results and discussion
3.1. Study of significant variables
During the prior investigation of TMOP tablets processing,
different variables (PEG 4000 amount in outer coat, MCC
amount in core tablets and coating thickness) were tested to
opt for the independent variables. Plots in Fig. 2 show the
corresponding dissolution curves of TMOP prepared according
Table 2 e Independent variables and their levels for
TMOP releasing.
Independent variables Levels
1.682 1 0 1 1.682
X1: PEG amount (mg) 0 16.22 40.00 63.78 80.00
X2: Thickness (mm) 4.60 4.76 5.00 5.24 5.40
X3: MCC amount (mg) 40.00 48.11 60 71.89 80.00
Dependent variables Constraints
Y1: CR of 4 h Minimize
Y2: CR of 14 h Minimize
Y3: CR of 24 h Maximize
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 0 8e2 1 7212to formulations in Section 2.4. Obvious differences were
observed in each group of formulations and these were also
reflected by the f2 value (data not shown) that all the f2 values
were less than 50%. Finally, the three factors (PEG 4000
amount, MCC amount and coating thickness) were recognized
as independent variables for TMOP releasing, and prepared for
the CCD study.
The time when 5% or more DIL was dissolving into the
dissolution medium was regarded as the termination of lag
time in this experiment. In general, 4-h lag time was appro-
priate for time-released preparations aiming at cardiovascular
disease. As shown in Fig. 2A, the produced TMOP tablets, with
either 40 mg or 60 mg PEG in outer layers, could generate the
qualified lag timewhile 80mg PEG leaded to amuch shortened
lag time (less than 2 h). The larger quantity of PEG had made
coating layer more porous, accelerating water molecule going
inside pharmaceutical core and enhancing permeation ability
for DIL solution rushing outside the membrane. Thus, the PEG
amount was negatively related to lag time. For coating layer, it
had been studied [20e22] that an increase in hardness or
compressive pressure could lead to the decrease in porosity,
slowing down the water inflow. Due to equivalent coating
quantity of TMOP in Fig. 2B, an increased pressure produced a
thinner coating layer where there's less porosity than thicker
one. The changes in outer layer had resulted in different lag
time of the compression-coated tablet. As shown in Fig. 2B, a
more than 6-h lag time was observed in the thinnest TMOP
(4.75e4.76 mm), while a just 2-h lag time in the thickest one
(4.98e5.00 mm). Significant difference was also seen in cu-
mulative release (CR). So the coating thickness had important
influence on TMOP profiles, too. Moreover, one of the core
materials, MCC, had turned out to be a delayed component for
DIL release. As was reflected in Fig. 2C, the MCC quantity was
negatively related to 4-h CR. The 4-h CR of DIL increased
obviously with MCC amount decreasing from 80 mg to 40 mg.
It was the water-insolubility of MCC that restrained inner DIL
from further hydration, so as to reducing the solution exuding
out. The existence of MCC prolonged core DIL release and
leaded to the extended lag time. Accompanying with the
coating layer, the MCC in pharmaceutical core surely facili-
tated forming the lag time for chronotherapeutics while the
PEG in coating layer retarded such process.
3.2. Statistical analysis of experimental data from CCD
study
The three-factor, five-level CCD for TMOP tablets was estab-
lished to explore the optimum levels of variables and the
coded and actual values of the variables are given in Table 2.
For three variables (n ¼ 3), the central composite design con-
sisted of 20 trials, including 2n (23 ¼ 8) factor points, 2n
(2  3 ¼ 6) axial points and 6 center points (six replications).
After dissolution tests to the 20 formulations generated by
CCD, the results of the experimental design indicated that this
system was significantly influenced by PEG, MCC, and the
thickness of coating layerswhich resulted in different lag time
and drug release for the evaluation of TMOP tablets. The data
were analyzed using Design-Expert software and Table 3
summarized that, the best fit for each of the responses Y1
(CR4 h), Y2 (CR14 h), and Y3 (CR24 h) were found for either thequadratic models or the linear models and the selected pre-
dicted r2 was underlined. Subsequently, the suggested math-
ematical models were chosen to describe the relevant
response variables.
The three-dimensional (3D) response surface plots (Fig. 3)
were used to illustrate the relationship between two inde-
pendent variables and response properties at center level of
other variable. Response surface plot in those figures
described the effects of the combination of every two vari-
ables, and their interaction on Y1, Y2 or Y3. For example, Fig. 3A
respectively shows the effect of PEG amount (X1) and coating
thickness (X2) on CR4 h (Y1) at center level of MCC loading (X3),
the effect of PEG amount (X1) and MCC loading (X3) on CR4 h
(Y1) while keeping coating thickness (X2) at center level, and
the effect of coating thickness (X2) and MCC loading (X3) on
CR4 h (Y1) at center level of PEG amount (X1) [23].
As shown in Table 3, the best fit for the responses Y1 (CR4 h)
was found for the quadratic models; compared to the linear
model and the two-factor model the quadratic model had the
largest predicted r2 values for Y1. Therefore the quadratic
model incorporating interactional and quadratic terms was
chosen to describe the effects of the variables. The regression
Eq. (2) of the fitted model constructed for CR4 h was presented
below:
Y1¼26:040460:065663X111:74775X2þ0:090588X3
þ0:011233X1X20:018232X2X3þ0:000115305X21þ1:32135X22
(2)
The results obtained in this design indicated that inde-
pendent factors affecting CR4 h were X1, X2, X3, X1X2, X2X3, X21
andX22, based on individual p values that were below 0.05 (data
not shown). The values of coefficientsX1 to X3 were associated
with the effect of these variables on the responses. The
interaction term (e.g., X1X2) showed how the response
changed when two factors simultaneously changed, while the
quadratic terms (X21 and X
2
2) suggest that there was a nonlinear
relationship in the response. As a consequence, quantitative
estimation of the significant models showed that coating
thickness (X2) had the prime influence on the CR4 h because of
its largest coefficient (11.75) than X1 (0.065663) and X3
(0.090588), suggesting that the tiny variations in the thickness
of TMOP tablets would change the CR4 h quit a lot. Moreover,
response surface plot in Fig. 3A described the effects of X1, X2
and X3 on Y1. It could be clearly seen that Y1 was strongly
affected by X2, since Y1 increased sharply with the increase of
X2, i.e. the thicker coating layer leaded to a shorten lag time.
Table 3 e Results of model summary statistics analysis for responses (The selected predicted r2 was underlined.).
Model Y1 (CR4 h) Y2 (CR14 h) Y3 (CR24 h)
r2 Adjusted r2 Predicted r2 r2 Adjusted r2 Predicted r2 r2 Adjusted r2 Predicted r2
Linear 0.7663 0.7225 0.6063 0.9019 0.8835 0.8201 0.803 0.7661 0.6377
2F 0.8262 0.746 0.5474 0.9215 0.8853 0.7528 0.9421 0.9154 0.8693
Quadratic 0.965 0.9335 0.7232 0.9562 0.9168 0.6678 0.983 0.9677 0.8699
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 0 8e2 1 7 213On the whole, X2 was the key factor affecting Y1. This illus-
tration was also confirmed by former researches concerning
compression-coated technology [24].
With regard to CR14h, the best fitted model was linear for a
predicted r2 ¼ 0.8201. It was observed in Fig. 3B that CR14h
could be improved significantly with PEG amount and coatingFig. 3 e Response surfaces for cumulative release in 4 h (A: Y1, CR
every two factors which were significantly influential.thickness increasingwhile the variation of MCC amountmade
an adverse effect. This was also indicated by Eq. (3) where the
positive coefficients (0.00882017, 0.71064) were respectively
attached to X1 (PEG amount), X2 (coating thickness) but a
negative one (0.00649618) for X3 (MCC amount); compared to
the X1 (PEG amount) and X3 (MCC amount), the X2 (coating4 h), 14 h (B: Y2, CR14 h) and 24 h (C:Y3, CR24 h) as functions of
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 0 8e2 1 7214thickness) still exerted the main influence on Y2 values for its
largest coefficients. A moderate CR14 h here was set for
balancing either fast release or slow release, maintaining
relatively permanent drug releasing during 24 h.
Y2 ¼ 2:88616þ 0:00882017X1 þ 0:71064X2  0:00649618X3 (3)
When CR24 h (Y3) was indicated as the response, the
mathematical relationship of the response Y3 on the three
significant independent variables X1, X2 and X3 can be
approximated by a quadratic model including 3 squared
terms, 3 two-factor interaction terms, 3 linear terms and 1
intercept term as shown below (Eq. (4)):
Y3 ¼ 2:16395þ 0:096332X1  1:26703X2  0:040999X3
0:018159X1X2 þ 0:000120221X1X3 0:0000734659X21 (4)
As shown in response surface plots (Fig. 3C) and Eq. (4),
CR24 h (Y3) was significantly influenced by the effects of X1, X2,
X3, and their interaction. It indicated that X1 and X2 had pos-
itive effects on CR24 h (Y3), i.e. the CR24 h (Y3) was increasing
with the increase of X1, X2. At the low level of X2, Y3 increased
from 33% to 85% with the increase of X1 from 16.22 mg to
63.78 mg. At the high level of X2, Y3 increased from 80% to 98%
as X1 increased from 16.22 mg to 63.78 mg. At the low level of
X1, Y 3 increased from 45% to 88% as X2 increased from
4.76 mm to 5.24 mm. At the high level of X1, Y3 increased from
95% to 98% as X2 increased from 4.76 mm to 5.24 mm. So it
could be clearly seen that Y3was strongly affected by X1, since
Y3 increased sharply with the increase of X1. On the other
hand, it was suggested that X3 had an adverse effect on CR24 h
(Y3). At low level of X1, Y3 decreased rapidly from 80 to 40% as
X3 increased from 20 to 80mg. At high level of X1, Y3 decreased
rapidly from 100 to 91% as X3 increased from 20 to 80mg. At to
X2, the trend of Y1 was similar to that at levels of X1.3.3. Optimization and validation
After analyzing the corresponding equations and the re-
sponds in response surface, a further optimum ranges for
each factor were found to generate TMOP tablets which0 4 8 12 16 20 24
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Fig. 4 e Dissolution profiles of TMOP tablets formulated by
optimal formulation in medium of different osmotic
pressure.depended on the prescriptive criteria with minimum CR4h,
minimum CR14h and maximum CR24h, by means of the
Design-Expert software. The suggested optimum formulation
was as follow: PEG amount (X1) 60.28 mg, coating thickness
(X2) 4.80 mm and MCC amount (X3) 65.36 mg. At these levels,
the predicted values of Y1 (CR4h), Y2 (CR14h), and Y3 (CR24h)
were 4.94%, 60.01%, and 90.20%, respectively. As indicated in
Fig. 4, the final TMOP tablets prepared with the suggested
formulation were observed as CR4h of (4.28 ± 1.19%), CR14h of
(61.07 ± 1.28%) and CR24h of (90.12 ± 1.03%) in medium of
purified water, which were in good agreement with the pre-
dicted values. The results confirm that the CCD method is
effective for predicting the impact of formulation composition
on the release profile of the DIL-TMOP tablets and providing
researchers more efficient approach for formulation
optimization.
3.4. Kinetics and release mechanism
The averaged dose release profiles of the compression-coated
tablets are shown in Fig. 4. When the osmotic pressure of the
release medium was equal to zero, i.e. purified water, an s-
shaped release profile was obtained and an obvious lag time
(drug releasing below 5%) was observed as the first 4 h; the
later 8-h profile was similar to zero-order release, followed by
a slightly sloping phase to the end. In order to exploring the
release mechanism of compression-coated tablets further,
complementary experiments were conducted in medium of
different osmotic pressures that was realized by adding
various quantity of NaCl. For an overview of the in vitro pro-
cess in Fig. 4, the release profile show high dependence on the
osmotic pressure of dissolution medium, and both average
release rate and cumulative release amount decrease as the
NaCl concentration of the dissolution medium increase. This
phenomenon indicates that self-made TMOP tablets are
authentic osmotic pressure-controlled delivery system.
Because this result is in accordance with the finding of a study
where the film was proven semi-permeable and the release
mechanism of pharmaceutical ingredient from a coated
formulation against the osmotic pressure of the release me-
dium should be known as osmotic pumping [21]. The higher
osmotic pressure in medium could reduce the trans-
membrane osmotic gap of osmotic device, which drove drug
to release, so the weaker driving force lead to a slower release
profiles in the medium of NaCl solution.
The internal-externalosmoticpressure gapofosmoticpump
is thedriving force fordrugrelease.Thus, the releasebehaviorof
the DIL osmotic pump tablet, so long as its saturated solution
still exists inside for a period of time, can be called zero-order
release. With the experimental data of the saturated concen-
tration of DIL (Ysat) core tablet volume (Vcore) and others, the
ending time of zero-order release can be obtained. Due to
excellentwater-solubility ofDIL, the timewhen the rest ofDIL in
core just right dissolved is the ending point. The remaining
quantity of DIL in coating pump could be calculated by the Ysat
and Vcore, so the DIL concentration in bulk medium (Cbulk) is ob-
tained, too.According to theobtainedCbulk,we canfigureout the
ending time of zero-order release in a certain time period based
onthe inintro c-tprofile.Asstatedabove, theCbulk iscalculatedat
77.39 ug/ml, so the cumulative release of DIL is gotten as 58.04%
a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 9 ( 2 0 1 4 ) 2 0 8e2 1 7 215which canbe locatedwithin the period of 12he14h in Fig. 4. For
more visual information, a segmented dissolution figure for
every 2 h is constructed in Fig. 5, and then an obvious decline of
released DIL is observed during 12 he14 h. It's the decreasing
internal-external osmotic pressure that leaded to a release
decline of DIL from osmotic pump system. Analysis shows that
the results complied well with the investigated findings of real
dissolution profile that there's an ending time of zero-order
release within 12 h and 14 h.
Savastano had proposed that the release mechanism for a
coated drug delivery system was the final outcome of three
rate-limiting steps which occurred during dissolution, i.e. (1)
water permeating across the outer film, (2) the drug core dis-
solving, and (3) the solution exuding out. Since the drug
molecule was embodied by water molecule throughout the
above mentioned steps, the transport and transformation of
water was tracked to develop a set of model equations. The
kinetic behavior of coated dosage in dissolution process is
confirmed to follow first-order regulation. Using Levenspiel's
method, the rate of water transforming from (1) to (3) is:
F ¼ 1 k2k3e
k1t
ðk1  k2Þðk1  k3Þ 
k1k3ek2t
ðk2  k1Þðk2  k3Þ 
k1k2ek3t
ðk3  k1Þðk3  k2Þ
(5)
F represents the release rate of drug and the kinetic con-
stants ki here represent first-order rate constants for each of
the three processes.
In the following analysis, Fmp represents the rate of drug
released from an osmotic pump coated with a microporous
membrane, and the relation between different kinetic con-
stants for each step on rate of appearance of drug in bulk
dissolution medium is simplified as follow [Eq. (6)]:
For k1 > >k2 þ k3; ðk1  k2Þzðk1  k3Þzk1;
So; Fmp ¼ 1þ k2e
k3t
k3  k2 
k3ek2t
k3  k2 (6)
Among the equation above, k2 ¼ kdYsatA0m0 , k3 ¼
DsrsYsatA
2
s
m0gs
, where
kd, m0 and A0 is dissolution rate constant, mass and surface0
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Fig. 5 e Column diagrams for segmented DIL release (every
2 h) from the TMOP in purified water (from 2 h to 14 h).area of the core tablet, respectively. Ysat is the saturated con-
centration of solute. Ds is diffusion coefficient of solute, rs the
density of coating layer,As the surface of layer and gs themass
of coating layer [25].
The value of the water inflow depends on the initial drug
concentration in the dissolved phase inside the core tablet. As
this concentration is assumed to be very close to zero, the
water inflow has a value close to zero at the initial time of the
simulation. So the initial time is deemed to lag time for TMOP
tablets. With the PEG in coating layer dissolving in medium,
the coat is changing into microporous. The core comes to
contact with dissolution medium and pharmaceutical in-
gredients started to dissolve. The water inflow then increases
due to the increased drug concentration inside the core as the
drug dissolves and the resulting high difference in osmotic
pressure across the coating. Now, it is a real osmotic pressure-
driven behavior following former models, and we began to
analyze the in vitro release at the termination of lag time, i.e.
the 5th hour. At the beginning, value of k2 of the DIL core tablet
is calculated as 14.3/h [26]. However, value of rs is diminishing
throughout the dissolution test due to soluble substance in
coating layer, so the k3 could not be calculated directly. Given
the situation that k3 represents the constant of water diffusion
from coating tablet to bulkmedium, and thewatermolecule is
embodied by drug molecule in permanent proportion
throughout the diffusion process, it could be derived from the
releasing profile as k3¼ 0.1035/h. Next, the value of k2 and k3 is
introduced into Eq. (6) to simulate the profile. With the com-
parison of simulated and observed data in Fig. 6, the correla-
tion between them is found significant. Thus, the Eq. (6) could
explain the in vitro behaviors of self-made TMOP tablets well
and it provides extra evidence for formulation design and
improvement.3.5. Pharmacokinetic study
A comparison of plasma concentrationetime profiles for the
TMOP tablets (test) and commercial preparations (reference)
are shown in Fig. 7. As expected, the oral absorption of the0 2 4 6 8 10 12 14 16 18 20
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Fig. 6 e Comparision of drug released profile observed and
simulated (the first 4 h' profile of observed one was
eliminated).
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Fig. 7 eMean plasma concentration of DIL after fed a single
oral administration test TMOP tablet and reference
sustained-release capsule.
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tablets.
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lag time exhibited before drug release. On the other hand, the
tested TMOP tablets exhibit an obvious lag time for about 4 h,
followed by a drug increase in the plasma.
The PK (pharmacokinetic) parameters for both formula-
tions are listed in Table 4. According to statistical analysis
done by an ANOVA test for repeated measurements, the
comparison of parameters with the two preparations shows
no significant differences for of Cmax and AUC0-48 h, but show
significant differences for Tmax. Consequently, the TMOP
tablets have turned out to prolong the lag time of drug release.
Bioequivalence of the two tablets is accepted with AUC0e48 h
and Cmax by the two one-sided tests. The relative bioavail-
ability of test TMOP tablets to reference tablets is 102% which
show that the generated lag time hadn't interfered with
following drug release. Fig. 8 show that these in vivo data of
TMOP tablets are consistent with the dissolution tests for a
good in vitroein vivo correlation of Y ¼ 1.15X þ 0.0634,
R ¼ 0.9586, indicating that the DIL absorption are primarily
attributed to the dissolution behavior of self-made devices,
and it could be predicted well by the in vitro tests. With the
application of TMOP, the chronotherapeutic purposes of lag
time and controlled release are achieved simultaneously.4. Conclusion
In the present work, a novel time-released osmotic pump
preparation for oral administration is developed by means of
compression-coated method. The optimal formulation isTable 4 e Pharmacokinetics parameters of DIL in dog
plasma after oral administration.
Parameters Reference Test ANOVA
Tmax (h) 4.00 ± 0.82 13.00 ± 1.16 P < 0.05
Cmax (ng/ml) 128.38 ± 29.46 111.56 ± 20.42 P > 0.05
AUC0e48 h (ng h/ml) 1625.10 ± 313.58 1654.97 ± 283.77 P > 0.05successfully obtained using the central composite design
method, avoiding a large number of trials for formulation
selection. With the optimum formulation, we construct a
time-released osmotic pump with CR4 h of 4.28%, CR14h of
61.07% and CR24h of 90.12% in dissolution tests. Compare with
conventional sustained-release preparations, the tested os-
motic pump tablets administrated by beagle dog exhibits not
only good oral bioavailability but also appropriate lag time
(almost 4 h) which is necessary for the chronotherapeutics.
The in vivo results demonstrate that the compression-coated
TMOP tablets can delivery drug in the gastrointestinal tract
in a manner similar to that in vitro and that it may be suitable
for the clinical use which is expected to display therapeutic
effects several hours after administration. Due to the limita-
tion of research conditions, there is some insufficiency about
the dissolving behavior of other model drug in the TMOP to be
done.
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